Earnings Feed
Start Free
Home/Filings/4/0000914190-13-000755
4//SEC Filing

Arno Therapeutics, Inc 4

Accession 0000914190-13-000755

CIK 0001195116operating
View on SEC.govCompany Profile

Filed

Oct 30, 8:00 PM ET

Accepted

Oct 31, 7:40 PM ET

Size

24.1 KB

Accession

0000914190-13-000755

Insider Transaction Report

Form 4
Period: 2013-10-29
Arno Therapeutics, IncARNI
Proniuk Stefan
VP of Product Development
Transactions
  • Conversion

    Common Stock

    2013-10-29$2.40/sh+8,887$21,329→ 9,381 total
  • Award

    Common Stock

    2013-10-29$2.40/sh+666$1,598→ 10,047 total
  • Conversion

    8% Senior Convertible Debentures

    2013-10-29−8,333→ 0 total
    Exercise: $2.40From: 2012-11-26Exp: 2015-11-26→ Common Stock (8,333 underlying)
  • Disposition to Issuer

    2012 Series B Warrants (right to buy)

    2013-10-29−8,333→ 0 total
    Exercise: $2.40From: 2012-11-26Exp: 2014-05-26→ Common Stock (8,333 underlying)
  • Award

    2012 Series B Warrants (right to buy)

    2013-10-29+8,333→ 8,333 total
    Exercise: $2.40From: 2013-10-29Exp: 2014-10-31→ Common Stock (8,333 underlying)
Holdings

  • Stock Option (right to buy)

    Exercise: $2.40Exp: 2021-09-19→ Common Stock (10,000 underlying)
    10,000

  • Stock Option (right to buy)

    Exercise: $2.40Exp: 2021-06-20→ Common Stock (17,187 underlying)
    17,187

  • Stock Option (right to buy)

    Exercise: $2.40Exp: 2021-06-20→ Common Stock (7,191 underlying)
    7,191

  • Stock Option (right to buy)

    Exercise: $2.40Exp: 2023-01-14→ Common Stock (6,875 underlying)
    6,875

  • Stock Option (right to buy)

    Exercise: $2.40Exp: 2023-01-14→ Common Stock (2,291 underlying)
    2,291

  • 2012 Series A Warrants (right to buy)

    Exercise: $2.40From: 2012-11-26Exp: 2017-11-26→ Common Stock (13,888 underlying)
    13,888
Footnotes (9)
  • [F1]On October 29, 2013, the Issuer and the holders of Issuer's 2012 8% Senior Convertible Debentures ("Holders"), which included the Reporting Person, entered into a Conversion Agreement ("Conversion Agreement") pursuant to which all Holders agreed to convert all outstanding principal and accrued interest under such debentures at a per share price of $2.40. Shares reflected represent shares issued to Reporting Person upon conversion of $21,329 of principal and accrued interest.
  • [F2]Pursuant to Conversion Agreement, Issuer also paid to each Holder additional 12 mos. interest for converting the debentures, which amount was satisfied by the issuance of common stock at a price of $2.40 per share. Shares reflected represented issuance in satisfaction of additional interest of $1,600.
  • [F3]25% vested on 6/22/12 and thereafter in 24 equal monthy installments.
  • [F4]On 6/22/2011, the Reporting Person was granted an option to purchase up to 112,500 shares of common stock of the Issuer. Up to 1/3 of the shares subject to the option may vest annually (or a pro rata portion thereof for a period of less than a full year) based on the achievement of certain performance milestones as determined by the Board of Directors (the 'Board') of the Issuer. On 1/17/2012, the Board determined that options for the prorated period ending 12/31/2011 would vest in the maximum potential amount of 20,034 shares. On 1/14/2013, the Board determined that options for the period ending 12/31/2012 would vest in the maximum potential amount of 37,500 shares.
  • [F5]50% vested on 9/19/11 and thereafter in 24 equal monthly installments.
  • [F6]1/3 vested on 1/14/13 and thereafter will vest in 24 equal monthy installments, commencing 1/31/13.
  • [F7]On 1/14/2013, the Reporting Person was granted an option to purchase up to 55,000 shares of common stock of the Issuer. 1/3 of the shares subject to the option were immediately vested and up to 1/2 of the remaining shares subject to the option may vest annually, based on the achievement of certain performance milestones as determined by the Board.
  • [F8]As a result of the Issuer's 10/29/13 private placement of common stock at $2.40/share, the exercise price and number of shares subject to the 2012 Series A Warrants were automatically adjusted to the exercise price and shares reflected, pursuant to anti-dilution adjustment provisions.
  • [F9]The two reported transactions involved an amendment of an outstanding warrant extending the expiration date from 5/26/14 to 10/31/14, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The "old" warrant was originally granted on 11/26/12.

Documents

1 file

Issuer

Arno Therapeutics, Inc

CIK 0001195116

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001195116

Filing Metadata

Form type
4
Filed
Oct 30, 8:00 PM ET
Accepted
Oct 31, 7:40 PM ET
Size
24.1 KB
View on SEC.gov